The second is the introduction of novel agents such as monoclonal antibodies, HDAC inhibitors, PI3K inhibitors, and anti-folate pralatrexate for treatment of PTCL. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.